Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012–2014
Matteo Serenari(Azienda USL di Bologna), Antonio Daniele Pinna(Cleveland Clinic), Michele Masetti(Azienda USL di Bologna), Giovanni Vennarecci(Carlo Forlanini Hospital), Roberto Montalti(Alfaisal University), Enrico Gringeri(University of Padua), Giorgio Ercolani, Umberto Cillo(University of Padua), Alessandro Ferrero, Fabio Forchino, Marco Massani(AULSS 2 Marca Trevigiana), Francesca Ratti(Vita-Salute San Raffaele University), Matteo Zanello(Ospedale Maggiore), Salvatore Gruttadauria, Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Bruno Nardo, Christian Cotsoglou(National Cancer Institute), Giuseppe Maria Ettorre(Carlo Forlanini Hospital), Elio Jovine(Azienda USL di Bologna), Elena Toschi(Joslin Diabetes Center), Erik Schadde(Edinburgh Royal Infirmary), Marco Vivarelli, Gian Luca Grazi(Azienda Ospedaliero-Universitaria Careggi), Nicolò Bassi(University of Padua), Luca Aldrighetti(Vita-Salute San Raffaele University)
Cited by 68
Related Papers
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821